Latest News - Aerie Pharmaceuticals

Tuesday, December 20, 2016 | Management/Leadership, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer

Aerie Pharmaceuticals announced the appointment of Judith J. Robertson as Chief Commercial Officer, reporting to Thomas Mitro, Aerie President and Chief Operating Officer. Ms. Robertson will be respon…

Read the full story

Wednesday, December 07, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan

Aerie Pharmaceuticals announced the completion of patient enrollment in the company’s second phase 3 registration trial (Mercury 2) of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%…

Read the full story

Thursday, October 27, 2016 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa

Aerie Pharmaceuticals reported the successful 90-day topline efficacy results of its Rocket 4 phase 3 clinical trial of product candidate Rhopressa, a novel once-daily eye drop being tested for its ab…

Read the full story

Friday, September 16, 2016 | Earnings & Financials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Raises $125 Million in Public Offerings

Aerie Pharmaceuticals announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting und…

Read the full story

Wednesday, September 07, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Submits New Drug Application to FDA for Rhopressa

Aerie Pharmaceuticals announced the submission of its new drug application (NDA) to the FDA for Rhopressa (netarsudil ophthalmic solution) 0.02%, according to a company news release. Rhopressa is a no…

Read the full story

Thursday, June 16, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa

Aerie Pharmaceuticals announced the completion of patient enrollment in Rocket 4, the company’s phase 3 clinical trial for Rhopressa (netarsudil ophthalmic solution) 0.02% intended to satisfy fi…

Read the full story

Thursday, May 05, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan

Aerie Pharmaceuticals announced the completion of patient enrollment in the company’s initial phase 3 registration trial (Mercury 1) of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02…

Read the full story

Monday, March 28, 2016 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan

Aerie Pharmaceuticals announced that on March 24, dosing commenced of the first patients enrolled in Mercury 2, the company’s second phase 3 registration trial of Roclatan (netarsudil/latanopros…

Read the full story

Thursday, March 17, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Update on Safety Results for Rhopressa QD

Aerie Pharmaceuticals reported an update including further details on the safety profile for Rhopressa QD, a once-daily eye drop being tested for its ability to lower IOP in patients with glaucoma or …

Read the full story

Tuesday, February 23, 2016 | Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week

Aerie Pharmaceuticals announced that two paper abstracts and two poster abstracts are scheduled to be presented at the American Glaucoma Society (AGS) 26th annual meeting, taking place March 3-6, 2016…

Read the full story

Thursday, February 18, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive 12-Month Safety Results for Rhopressa

Aerie Pharmaceuticals reported the successful 12-month interim safety results of Rocket 2, Aerie’s second phase 3 registration trial for Rhopressa (netarsudil ophthalmic solution) 0.02%, a novel…

Read the full story

Thursday, November 05, 2015 | Conferences, Aerie Pharmaceuticals

Aerie Pharmaceuticals to Participate in Several Conferences in November

Aerie Pharmaceuticals announced that company management will present an overview of the company at the following conferences in November. Ophthalmology Innovation Summit (OIS) at the American So…

Read the full story

Thursday, September 24, 2015 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa

Aerie Pharmaceuticals announced that on September 23, dosing commenced of the first patients enrolled in Rocket 4, the company’s fourth phase 3 clinical trial of Rhopressa, a once-daily, triple-…

Read the full story

Monday, September 21, 2015 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan

Aerie Pharmaceuticals announced that on September 18, dosing commenced of the first patients enrolled in Mercury 1, the company’s first phase 3 registration trial of Roclatan, a once-daily, quad…

Read the full story

Wednesday, September 16, 2015 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Rhopressa Phase 3 Efficacy Results

Aerie Pharmaceuticals reported that its second phase 3 trial, Rocket 2, achieved its primary efficacy endpoint demonstrating noninferiority of Rhopressa compared to timolol. Rhopressa, a once-daily, t…

Read the full story
Load More